NCT00709761 - Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 2, 2008

Primary Completion Date

January 5, 2011

Study Completion Date

January 3, 2018

Conditions

Neoplasms, Breast

Interventions

DRUG

Lapatinib/nab-Paclitaxel

This was an open-label, single-arm, multi-center, Phase II study to determine the activity of nab-paclitaxel plus lapatinib (TYKERB) in the first and second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC). Subjects were to receive nab-paclitaxel (100 mg/m2 intravenously on Day 1, 8, 15, every 28 days (q28) days plus lapatinib (1000 mg once daily on a continuous basis).

Trial Locations (13)

10065

Novartis Investigative Site, New York

14623

Novartis Investigative Site, Rochester

23230

Novartis Investigative Site, Richmond

24153

Novartis Investigative Site, Salem

30341

Novartis Investigative Site, Atlanta

33916

Novartis Investigative Site, Fort Myers

37203

Novartis Investigative Site, Nashville

44106

Novartis Investigative Site, Cleveland

45242

Novartis Investigative Site, Cincinnati

90813

Novartis Investigative Site, Long Beach

91750

Novartis Investigative Site, La Verne

98201

Novartis Investigative Site, Everett

98405

Novartis Investigative Site, Tacoma